Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Webcasts|July 20, 2023

A Novel Ion Exchange Phase media for High-Resolution Charge Profiling of Various Biopharmaceutical Modalities

Webinar Date/Time: Wednesday, August 9, 2023 at 5pm CEST | 11am EDT | 8am PDT

Learn about a novel stationary phase media for ion exchange separations and the use of LC-HRAM MS instruments for charge variant analysis and viral vectors

Register Free: https://www.biopharminternational.com/bp_w/ion-exchange

Event Overview:

Ion exchange separations are routinely used for quality attribute profiling of various biopharmaceutical format, be it charge variant analysis of monoclonal antibodies and recombinant proteins or determination of the capsid fill state of viral vectors for gene therapy.
This webinar presents a novel stationary phase media for ion exchange separations that delivers the highest resolution separation with lot-to-lot consistency. Application results for charge variant profiling of monoclonal antibodies and their various biosimilars, and the determination of full and empty AAV viral vector chromatographic separation hyphenated with native MS and direct mass technology mode charge detection will be described.
Key Learning Objectives:

  • Learn about a novel monodisperse ion exchange media for strong cation and anion exchange separation to accelerate your analytical development.
  • Learn about using LC–HRAM MS instruments for charge variant analysis of protein biopharmaceutics and full/empty AAV capsid ratio CQAs determination.


Who Should Attend:

For biopharmaceutical analytical staff who need reliability and resolution power when identifying and quantifying charge variants profiles of proteins in analytical development and QC environments.

Speakers:

Ke Ma, PhD
Staff Scientist, Research & Development
Thermo Fisher Scientific

Dr Ke Ma completed his PhD in Analytical Chemistry at Michigan State University in 2019. Following graduation, he joined PPD as a senior scientist, where he specialized in the development and validation of methods for small molecule therapeutics. Later, in 2022, Dr Ma joined Thermo Fisher Scientific, where he currently focuses on developing new bio-columns for various applications in large molecule therapeutics, including IEX, RP, SEC, and more.

Jonathan Bones, PhD
Principal Investigator
The National Institute for Bioprocessing Research and Training (NIBRT)

Dr Jonathan Bones received his PhD in Analytical Chemistry from Dublin City University in 2007. He then transitioned to NIBRT, to Professor Pauline M. Rudd’s lab. In 2010, Dr Bones moved to the Barnett Institute of Chemical and Biological Analysis at Northeastern University, Boston, to work with Professor Barry L. Karger. In 2012, he returned to NIBRT, where he currently services as a principal investigator of the NIBRT Characterization and Comparability Laboratory. Dr Bones is also an associate professor for the School of Chemical and Bioprocess Engineering at University College Dublin.

Register Free: https://www.biopharminternational.com/bp_w/ion-exchange


Related to this article

The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.
Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.